Business Context and Reporting Period
This Form 8-K was filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on February 5, 2020. The registrant is incorporated in Delaware and trades on the NASDAQ Global Market under the symbol ZFGN. The filing serves as a Regulation FD disclosure regarding upcoming investor meetings.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding disclosure events rather than a periodic financial statement.
Material Changes
No material financial changes or operational updates are detailed in the text of this filing. The primary event is the scheduled participation of management in investor meetings.
Guidance, Outlook, and Management Commentary
- Investor Meetings: Management will participate in upcoming meetings with investors.
- Exhibit 99.1: A presentation used for these meetings is attached as Exhibit 99.1.
- Legal Status of Information: The information in this filing and the attached presentation is furnished and not deemed "filed" under Section 18 of the Exchange Act, nor is it subject to the liabilities of that section, except as expressly referenced in other filings.
Investor Verification Checklist
- Verify the company name is Zafgen, Inc. (ZFGN), as the input metadata incorrectly referenced Larimar Therapeutics, Inc.
- Review Exhibit 99.1 (the investor presentation) for specific financial data, pipeline updates, or strategic guidance not included in the 8-K text.
- Confirm the date of the investor meetings to assess the timeliness of the disclosed information.
- Note that the presentation materials are not legally "filed" for liability purposes under Section 18 of the Exchange Act.